More muscle from eggs? Proteo-lipid complex may help prevent age-associated loss of muscle-mass

In older people, low muscle mass is strongly associated with reduced functional capacity and an increased risk of disability. Myostatin is a negative regulator of muscle growth and has become an important target for pharmaceutical companies designing therapeutics to address age-associated muscle loss.

Anti-myostatin drugs increase muscle size and strength in preclinical studies. Fortetropin is a proteo-lipid complex made from fertilized egg yolk and shows anti-myostatin activity. When Fortetropin is provided as a supplement, lowered circulating myostatin levels are observed both in rodents and in young men. Fortetropin in combination with resistance exercise also lowers myostatin and increased lean body mass.

Continue reading “More muscle from eggs? Proteo-lipid complex may help prevent age-associated loss of muscle-mass”

Proteomics from a Different Point of View: Introducing ProAlanase, the Newest Mass-Spec Grade Protease from Promega

Sometimes, when using trypsin to study a protein sequence or protein modifications, sequence coverage just isnโ€™t quite as complete as youโ€™d like. Looking for a protease with novel cleavage specificity or a protease that functions well in a low pH environment? Promega has a protease for that.

ProAlanase is a new site-specific endoprotease that preferentially cleaves proteins on the C-terminal side of proline and alanine amino acids. The unique cleavage specificity of ProAlanase (also known as An-PEP or EndoPro; 1โ€“3) can help to uncover parts of the proteome not previously accessible with proteases typically used in proteomic studies.

Continue reading “Proteomics from a Different Point of View: Introducing ProAlanase, the Newest Mass-Spec Grade Protease from Promega”

CRISPR/Cas9 HiBiT Knock-In: A Scalable Approach for Studying Endogenous Protein Dynamics

Studying protein function in live cells is limited by the tools available to analyze the expression and interactions of those proteins. Although mass spectrometry and antibody-based protein detection are valuable technologies for protein analysis, both methods have drawbacks that limit the range of targets and contexts in which proteins can be investigated.

Mass spectrometry is often poor at detecting low-abundance proteins. Antibody-based techniques require high quality, specific antibodies, which can be difficult to impossible to acquire. Both methods require cell lysis, preventing real-time analysis and limiting the physiological relevance, and both methods can be limiting for higher-throughput analysis. While plasmid-based overexpression of tagged target proteins simplifies detection and can allow for real time analysis, protein levels donโ€™t typically resemble endogenous levels. Overexpression also has the potential to create experimental artifacts or limit the dynamic range of an observed response.

In 2018, Promega R&D scientists published a paper in ACS Chemical Biology demonstrating the use of CRISPR/Cas9 to integrate the 11 amino acid, bioluminescent HiBiT tag directly into the genome to serve as an easily measured reporter for endogenous proteins. This provides a highly quantitative method for investigating cellular protein dynamics that sidesteps the need for cloning and other drawbacks to conventional methods, including the ability to measure changing protein dynamics in real-time. (For more details about CRISPR/Cas9 knock-in tagging and other applications, read this blog.)

While their findings showed that this method provides efficient and specific tagging of endogenous proteins, the research was limited to just five different proteins within a single signaling pathway in two cell lines. This left unanswered questions about whether this approach was scalable, had broader applications and how accurately the natural biology of the cells was represented.

Continue reading “CRISPR/Cas9 HiBiT Knock-In: A Scalable Approach for Studying Endogenous Protein Dynamics”

Designing BET(ter) Inhibitors to Guide Therapy for Cancer and Inflammatory Diseases

bet proteins brd nanoluc

Transcriptional activation of genes within the nucleus of eukaryotic cells occurs by a variety of mechanisms. Typically, these mechanisms rely on the interaction of regulatory proteins (transcriptional activators or repressors) with specific DNA sequences that control gene expression. Upon DNA binding, regulatory proteins also interact with other proteins that are part of the RNA polymerase II transcriptional complex.

One type of transcriptional activation relies on inducing a conformational change in chromatin, the DNA-protein complex that makes up each chromosome within a cell. In a broad sense, โ€œextendedโ€ or loosely wound chromatin is more accessible to transcription factors and can signify an actively transcribed gene. In contrast, โ€œcondensedโ€ chromatin hinders access to transcription factors and is characteristic of a transcriptionally inactive state. Acetylation of lysine residues in histonesโ€”the primary constituents of the chromatin backboneโ€”results in opening up the chromatin and consequent gene activation. Disruption of histone acetylation pathways is implicated in many types of cancer (1).

Continue reading “Designing BET(ter) Inhibitors to Guide Therapy for Cancer and Inflammatory Diseases”

NanoBRET™ Assays to Analyze Virus:Host Protein:Protein Interactions in Detail

Recently, Gordon et al. published an atlas of protein:protein interactions of all proposed SARS-CoV-2 proteins expressed individually in HEK 293 cells (Table 1). The study tagged each of the viral proteins with an epitope tag and performed a pull-down of the expressed protein followed by trypsin digestion and mass spec analysis, a process referred to as affinity purificationโ€“mass spec analysis. The group identified 332 human proteins interacting with 27 SARS-CoV-2 proteins.

The interactions identified in the HEK 293 cells helped Appelberg et al. analyze interactions over time in SARS-CoV-2-infected Huh7 cells. Gordon et al. used the PPI data to identify FDA-approved drugs, drugs in clinical trials, and pre-clinical compounds that bound to the identified human proteins and labs in New York and Paris tested some of these drugs for antiviral effects.   

Table 1. The general functional area of human proteins identified to interact with individually expressed SARS-CoV-2 proteins as reported by Gordon, et al. (1). The SARS-CoV-2 proteins are classified as non-structural proteins (nsp#), structural proteins (E, M, and N) and accessory proteins (orf#).  
Continue reading “NanoBRET™ Assays to Analyze Virus:Host Protein:Protein Interactions in Detail”

NanoLucยฎ Luciferase Powers More than Reporter Assays

Bright NanoLucยฎ Luciferase

What happens when you engineer a small, super bright luciferase? A generation of new tools. We’ve highlighted many of the papers and new applications that NanoLucยฎ luciferase has enabled on this blog. Introduced first as a reporter enzyme to assess promoter activity, NanoLucยฎ has since become the foundation for bioluminescent tools that reveal endogenous protein dynamics, target engagement, protein degradation, immunodetection and more. Much of that biology was largely invisible before these tools existed. So where did NanoLucยฎ come from, and how does one enzyme power so many research capabilities? Read on for a primer on the technologies and applications built from this enzyme over the last decade.

Continue reading “NanoLucยฎ Luciferase Powers More than Reporter Assays”

From Live Cells to Lysates: Adapting NanoBiT to a Biochemical Assay Format

The ability to target protein interactions with low solubility or weak binding affinities can present a significant challenge when it comes to drug screening. The beauty of these types of challenges we often face in the lab is that finding solutions to these problems doesn’t necessarily require brand new tools. Sometimes we already have the right tools in our arsenal and, with just a little creativity and collaboration, they can be adapted to address the challenge at hand.

In the following video, Dr. Mohamed (Soly) Ismail, a Postdoctoral Fellow at the Downward Lab of the Francis Crick Institute, presents the perfect example of this with his novel approach to the NanoBiTยฎ Protein:Protein Interaction Assay. Through a collaboration with Promega R&D Scientists, Dr. Ismail has translated the assay into a cell-free, biochemical format, termed the NanoBiT Biochemical Assay (NBBA).

Continue reading “From Live Cells to Lysates: Adapting NanoBiT to a Biochemical Assay Format”

Giant Rodent, Lowered Cancer Rates: What Genetic Analysis Reveals about the Capybara and Cancer

Do you find the thought of a giant rodent off-putting? Do your thoughts go to huge rats running amuck in dark allies, threatening unsuspecting passers by?

I personally hold rodents in low esteem. Rats, miceโ€ฆwho needs them? With the exception of cavies. I spent countless hours as a child playing with guinea pigs. We had as many as 16 of these little rodents at one time (the males are very capable of chewing or climbing out of cardboard boxes to reach a female in the next box). The baby guinea pigs were very cute and the adults had quite pronounced personalities, and a lot of attitude.

It was this history with guinea pigs that made me interested in learning more about the largest rodent in the world, the South American capybara (Hydrochoerus hydrochaeris). These family-oriented herbivores are found in savannas and forested areas, living in groups of as many as 100 members. They are excellent swimmers and can remain underwater for as long as 5 minutes. In fact, capybara mate only in the water. (Perhaps it’s not surprising then that the South American alligator, the caiman, is one of the capybaraโ€™s greatest predators.)

Photos of an adult male capybara.
A male capybara, with a scent gland (called a morillo) on his head. Photo by: Charles J Sharp – Own work, from Sharp Photography, sharpphotography, CC BY-SA 4.0.

With their squared-off nose and lack of tail, capybaras actually resemble guinea pigs. However, these oversized cavies weigh as much as 40 pounds. and can reach 24โ€ at the shoulder, the size of an average standard poodle. Guinea pigs, on the other hand, weigh in at 2โ€“3 pounds, and are 3โ€“4โ€ tall.

Their proportions make capybaras 60 times more massive than their closest relatives, rock cavies (Kerodon sp.) and 2,000 times more massive than the common mouse (Mus musculus). This tremendous size difference is why Herrera-รlvarez et al. took a closer look at the capybara, studying its propensity to develop cancer and other tradeoffs that would seem to coincide with its exceptional size.

Continue reading “Giant Rodent, Lowered Cancer Rates: What Genetic Analysis Reveals about the Capybara and Cancer”

Targeted Protein Degradation: A Bright Future for Drug Discovery

targeted protein degradation and protacs

Our cells have evolved multiple mechanisms for โ€œtaking out the trashโ€โ€”breaking down and disposing of cellular components that are defective, damaged or no longer required. Within a cell, these processes are balanced by the synthesis of new components, so that DNA, RNA and proteins are constantly undergoing turnover.

Proteins are degraded by two major components of the cellular machinery. The discovery of the lysosome in the mid-1950s provided considerable insight into the first of these degradation mechanisms for extracellular and cytosolic proteins. Over the next several decades, details of a second protein degradation mechanism emerged: the ubiquitin-proteasome system (UPS). Ubiquitin is a small, highly conserved polypeptide that is used to selectively tag proteins for degradation within the cell. Multiple ubiquitin tags are generally attached to a single targeted protein. This ill-fated, ubiquitinated protein is then recognized by the proteasome, a large protein complex with proteolytic activity. Ubiquitination is a multistep process, involving several specialized enzymes. The final step in the process is mediated by a family of ubiquitin ligases, known as E3.

Continue reading “Targeted Protein Degradation: A Bright Future for Drug Discovery”

NanoLuc: Tiny Tag with a Big Impact

Synthetic biologyโ€”genetically engineering an organism to do or make something usefulโ€”is the central goal of the iGEM competition each year. After teams conquer the challenge of cloning their gene, the next hurdle is demonstrating that the engineered gene is expressing the desired protein (and possibly quantifying the level of expression), which they may do using a reporter gene.

Reporters can also play a more significant role in iGEM projects when teams design their organism with reporter genes to detect and signal the presence of specific molecules, like environmental toxins or biomarkers. Three of the iGEM teams Promega sponsored this year opted to incorporate some version of NanoLucยฎ Luciferase into their projects.

NanoLucยฎ luciferase is a small monomeric enzyme (19.1kDa, 171 amino acids) based on the luciferase from the deep sea shrimp Oplophorus gracilirostris. This engineered enzyme uses a novel substrate, furimazine, to produce high-intensity, glow-type luminescence in an ATP-independent reaction. Unlike other molecules for tagging and detecting proteins, NanoLucยฎ luciferase is less likely to interfere with enzyme activity and affect protein production due to its small size.

NanoLucยฎ Luciferase has also been engineered into a structural complementation reporter system, NanoBiTยฎ Luciferase, that contains a Large subunit (LgBiT) and two small subunit options: low affinity SmBiT and high affinity HiBiT. Together, these NanoLucยฎ technologies provide a bioluminescent toolbox that was used by the iGEM teams to address a diverse set of biological challenges.

Here is an overview of each teamโ€™s project and how they incorporated NanoLucยฎ technology.

Continue reading “NanoLuc: Tiny Tag with a Big Impact”